Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117611 · ClinicalTrials.gov registry record · Phase 4
Xolair in Patients With Chronic Sinusitis
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00117611 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 14 participants.
The verdict
NCT00117611, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
Interventions
- DRUG Anti-IgE antibody omalizumab or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117611
The ClinicalTrials.gov registry entry for NCT00117611 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-IgE antibody omalizumab or placebo is the first listed.
NCT00117611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117611 about?
NCT00117611 is a clinical study titled "Xolair in Patients With Chronic Sinusitis". The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
What is the current status of trial NCT00117611?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2005-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00117611?
The interventions under investigation include: Anti-IgE antibody omalizumab or placebo (DRUG).
Who is sponsoring clinical trial NCT00117611?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.